Previous close | 101.40 |
Open | 100.20 |
Bid | N/A x N/A |
Ask | N/A x N/A |
Day's range | 100.20 - 101.60 |
52-week range | 100.20 - 101.60 |
Volume | |
Avg. volume | 0 |
Market cap | 260.608B |
Beta (5Y monthly) | N/A |
PE ratio (TTM) | 21.04 |
EPS (TTM) | N/A |
Earnings date | N/A |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | N/A |
RAHWAY, N.J., June 05, 2024--Merck to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference
RAHWAY, N.J., May 29, 2024--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the U.S. Food and Drug Administration (FDA) has accepted for priority review a new supplemental Biologics License Application (sBLA) seeking approval for KEYTRUDA, Merck’s anti-PD-1 therapy, in combination with chemotherapy, for the first-line treatment of patients with unresectable advanced or metastatic malignant pleural mesothelioma. The FDA has set a Prescription Drug User Fee
RAHWAY, N.J. & NEW YORK, May 29, 2024--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, and Eyebiotech Limited (EyeBio), a privately held ophthalmology-focused biotechnology company, today announced that the companies have entered into a definitive agreement under which Merck, through a subsidiary, will acquire EyeBio.